April 17, 2017
A putative class of investors in Amicus Therapeutics Inc. who said the company's misleading statements about their interaction with the U.S. Food and Drug Administration amounted to securities fraud asked a New Jersey federal court on Friday to approve a $3.75 million settlement that would end the litigation before the court even considered dismissal.
October 08, 2015
Amicus Therapeutics Inc. misled investors about the prospects of a new drug to treat a rare genetic disease, then reversed course two weeks later and sent stock prices plummeting, a shareholder alleged Wednesday in a proposed class action in New Jersey federal court.